# Guardian Pharmacy Services, Inc. (GRDN)

> Source: Nexqual · https://nexqual.com/GRDN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Guardian Pharmacy Services, Inc. (GRDN), nexqual.com/GRDN" · informational, not investment advice.

**Price:** USD 39.59 (+1.56% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 38.98 · day 39.31–39.97 · 52w 26.34–48.33 · market cap $2.51B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.46B, net income $65.9M (4.5% margin) (SEC filings).
- Valuation: P/E 38.0x.
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 49.86 (range 47–52).
- Total return with dividends: 1Y +41.2% vs S&P 500 +14.9%; 5Y +123.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.31, revenue estimate $366M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2024 | FY2025 | TTM |
|---|---|---|---|
| Revenue | $1.23B | $1.45B | $1.46B |
| Gross profit | $244M | $293M | — |
| Operating income | -$62.9M | $72.7M | $85.4M |
| Net income | -$110M | $49.2M | $65.9M |
| Free cash flow | $43.3M | $86.8M | — |
| Gross margin | 19.9% | 20.2% | — |
| Operating margin | -5.1% | 5.0% | 5.8% |
| Net margin | -9.0% | 3.4% | 4.5% |
| Revenue growth | — | +17.9% | — |
| Cash + short-term investments | $4.7M | $65.6M | — |
| Total debt | $0K | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 38.0x · P/S 1.7x · P/B 9.7x · Earnings yield 2.63%

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 49.86 (low 47, high 52).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Keybanc | Initiated | Overweight | $52 |
| 2026-09-21 | Truist Securities | Target raised | Buy | $47 → $51 |
| 2026-08-07 | Oppenheimer | Target raised | Outperform | $43 → $49 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2024-09-23) |
|---|---|---|
| Total return | +41.2% | +123.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +41.4% | +47.1% |
| Volatility (annualized) | 40.9% | 42.6% |
| Max drawdown | -18.8% (Sep 2026→Oct 2026) | -26.1% (Dec 2024→Mar 2025) |

## Peers (Medical Care Facilities)
BKD (Brookdale Senior Living Inc.) USD 10.19 +1.09% · MD (Pediatrix Medical Group, Inc.) USD 29.55 +5.16% · ADUS (Addus HomeCare Corporation) USD 122.67 +4.00% · AVAH (Aveanna Healthcare Holdings Inc) USD 13.32 +2.54% · ACHC (Acadia Healthcare Company, Inc.) USD 31.88 +1.43% · SGRY (Surgery Partners, Inc.) USD 15.9 +3.25%

## More
Full page: https://nexqual.com/GRDN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-06)

- "We also continued to expand profitability, reflecting the benefits of scale, purchasing leverage and improved operating efficiency." Burke continued, "Our second-quarter performance, together with our outlook for the remainder of the year, gives us the confidence to raise our 2026 guidance." FY 2026 Outlook – Updating Guidance The guidance below excludes any future acquisitions."
- "Updated Guidance Previous Guidance Revenue $ 1.43 billion - $1.45 billion $ 1.40 billion -$1.42 billion Adjusted EBITDA $ 129 million -$131 million $ 122 million -$127 million M&A and Greenfields Subsequent to quarter-end, Guardian completed the acquisition of Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia."

Analysts expect $365.8M for the current quarter, -74.6% vs the guidance midpoint $1.44B. Source: https://www.sec.gov/Archives/edgar/data/1802255/000119312526338032/d160709dex991.htm

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.31 | $0.30 | +4.2% | $365.8M | 7 |
| Next quarter (ends 2026-12-31) | $0.41 | $0.41 | +1.1% | $387.8M | 7 |
| Current fiscal year (ends 2026-12-31) | $1.30 | $1.26 | +3.3% | $1.44B | 7 |
| Next fiscal year (ends 2027-12-31) | $1.43 | $1.36 | +5.6% | $1.53B | 7 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±14.2%; last 8 reports averaged ±5.7%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 62.8% | ±14.2% |
| 2027-01-15 | 84 | 50.6% | ±19.2% |
| 2027-04-16 | 175 | 49.3% | ±27.3% |